ライフサイエンスコーパス: liposomal doxorubicin

1 ribution of the intratumoral accumulation of liposomal doxorubicin.

2 ry of systemic antineoplastic agents such as liposomal doxorubicin.

3 and toxicity outcomes also favored pegylated-liposomal doxorubicin.

4 atients who were then treated with pegylated-liposomal doxorubicin.

5 ding an additional anti-tumor adjuvant agent liposomal doxorubicin.

6 eekly doses of gemcitabine, vinorelbine, and liposomal doxorubicin.

7 on was sufficient to increase sensitivity to liposomal doxorubicin.

8 after intravenous administration of (99m)Tc-liposomal doxorubicin.

9 subsequently, the animals were treated with liposomal doxorubicin.

10 n of therapeutic responsiveness of tumors to liposomal doxorubicin.

11 thin 3 months of discontinuing, topotecan or liposomal doxorubicin.

12 90 degrees C RF dose either with or without liposomal doxorubicin.

13 treated with RF ablation (2.3 cm +/- 0.1) or liposomal doxorubicin (0.0 cm +/- 0.0) alone (P < .01).

14 Intravenous liposomal doxorubicin (1 mg in 500 micro L, n = 6) or in

15 r RF (70 degrees C for 5 minutes) alone, (b) liposomal doxorubicin (1 mg) alone, (c) RF ablation foll

16 es, 2000-mA pulsed technique) followed by IV liposomal doxorubicin (10 mg per animal) (n = 6), RF abl

17 ved doxorubicin, epirubicin or non-pegylated liposomal-doxorubicin (10 mg/kg) and cardiac function wa

18 (n=8, each) that received a combined RF and liposomal doxorubicin (15 min post-RF, 8 mg/kg) either w

19 valuated rituximab 375 mg/m(2) combined with liposomal doxorubicin 20 mg/m(2) (R-Dox) every 3 weeks i

20 e treated for six 3-week cycles of pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (

21 andomly assigned to receive either pegylated-liposomal doxorubicin (20 mg/m2) or the combination of d

22 The recommended phase II dose is liposomal doxorubicin 24 mg/m(2) on day 1 and gemcitabin

23 Patients received pegylated liposomal doxorubicin 24 mg/m2 intravenously on day 1, p

24 arily platinum resistant, 59.1% had received liposomal doxorubicin, 25% topotecan, 15.9% both agents,

25 in canine sarcomas treated with RF ablation-liposomal doxorubicin (3.7 cm +/- 0.6) compared with tha

26 ide 25 mg, bortezomib 1.3 mg/m(2), pegylated liposomal doxorubicin 30 mg/m(2), and dexamethasone 20/1

27 0 degrees C +/- 2, 5 minutes) followed by IV liposomal doxorubicin (5 mg per rabbit, 1 mg per rat) or

28 Patients received intravenous (I.V.) liposomal doxorubicin 50 mg/m2 every 3 weeks with a dose

29 Gylated liposomes (1295 MBq/kg), (e) (186)Re-liposomal doxorubicin (555 MBq/kg), (f) PEGylated liposo

30 r photodynamic damage, resulting in enhanced liposomal doxorubicin accumulation in tumors.

31 (38.9 ng/g +/- 8.0), and tumors treated with liposomal doxorubicin alone (43.9 ng/g +/- 6.7 for all r

32 mal) (n = 6), RF ablation alone (n = 6), and liposomal doxorubicin alone (n = 4).

33 with (186)Re-liposomal doxorubicin than with liposomal doxorubicin alone (tumor volume, 2.26 cm(3) +/

34 0.38; P < .001 vs all groups except (186)Re-liposomal doxorubicin alone).

35 e, 16.5 days +/- 3.2 for tumors treated with liposomal doxorubicin alone, and 26.6 +/- 5.3 days with

36 Stealth liposomal doxorubicin (Alzal Corp, Palo Alto, CA) has a

37 The use of RF ablation with liposomal doxorubicin and (186)Re-liposomal doxorubicin

38 nger than did animals that received combined liposomal doxorubicin and 70 degrees C RF ablation (P <.

39 Additionally, animals that received combined liposomal doxorubicin and 90 degrees C RF ablation survi

40 amycin (mTOR) inhibition in combination with liposomal doxorubicin and bevacizumab in patients with a

41 ines of conventional chemotherapy (pegylated liposomal doxorubicin and docetaxel) was treated with le

42 The combination of liposomal doxorubicin and gemcitabine is an active and w

43 +/- 1.5) was observed with a combination of liposomal doxorubicin and RF ablation (P <.001, for all

44 in tumors treated with temperature-sensitive liposomal doxorubicin and ultrasound hyperthermia.

45 Prior treatment with liposomal doxorubicin and/or gemcitabine was not allowed

46 (PegIntron and Pegasys), and nanoparticles (Liposomal-Doxorubicin and quantum-dots).

47 in (1 mg) alone, (c) RF ablation followed by liposomal doxorubicin, and (d) no treatment.

48 bination lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (RVDD) in newly

49 se of less cardiotoxic alternatives, such as liposomal doxorubicin, and intensity-modulated radiation

50 These agents include gemcitabine, topotecan, liposomal doxorubicin, and prolonged oral etoposide.

51 Liposomal doxorubicin at doses of 40, 50, 60, and 80 mg/

52 acizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, bevacizumab, and everolimus (DAE)

53 years; range, 37-79 years) were treated with liposomal doxorubicin, bevacizumab, and temsirolimus (DA

54 Liposomal doxorubicin, bevacizumab, and the mTOR inhibit

55 reduce the sensitivity of HGSC cell lines to liposomal doxorubicin, but not to doxorubicin, whereas L

56 wed by intravenous administration of 1 mg of liposomal doxorubicin, (c) RF ablation followed by intra

57 Liposomal doxorubicin can be reliably delivered to liver

58 Intravenous administration of liposomal doxorubicin can improve RF ablation, since it

59 or reduced cardiac toxicity of non-pegylated-liposomal doxorubicin characterized by attenuation of RO

60 g or efficacy for H2009.1 tetrameric peptide liposomal doxorubicin, compared to control peptide and n

61 igned a fibronectin-targeting CREKA-modified liposomal doxorubicin (CREKA-Lipo-Dox) for the therapy o

62 for 5 minutes), (b) PEGylated liposomes, (c) liposomal doxorubicin, (d) (186)Re-PEGylated liposomes (

63 2) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem melphalan (1

64 e impact of three weekly sessions of FUS and liposomal doxorubicin (DOX) in 9L rat glioma tumors.

65 herapeutic outcomes than clinically approved liposomal doxorubicin (Doxil) in HER2-overexpressing BT4

66 ining radiofrequency (RF) ablation with i.v. liposomal doxorubicin (Doxil) increases intratumoral dox

67 nced the efficacy of i.v. injected pegylated liposomal doxorubicin (Doxil).

68 Patients received 20 mg/m2 pegylated-liposomal doxorubicin (Doxil; Sequus Pharmaceuticals, In

69 tandard agents with rituximab plus pegylated liposomal doxorubicin (DR-COP) in an attempt to provide

70 rugs include topotecan, etoposide, pegylated liposomal doxorubicin, epirubicin, gemcitabine, altretam

71 Use of RF ablation combined with liposomal doxorubicin facilitates increased tissue coagu

72 nimals were treated with intravenous (99m)Tc-liposomal doxorubicin followed by RF tumor ablation at a

73 free doxorubicin and was superior to that of liposomal doxorubicin formulations.

74 Spheroids were dosed with liposomal doxorubicin, free doxorubicin, or media contro

75 dependent on the timing of administration of liposomal doxorubicin from 3 days before to 24 hours aft

76 ation with liposomal doxorubicin and (186)Re-liposomal doxorubicin further improved tumor control (tu

77 In HL-1 cells, non-pegylated liposomal-doxorubicin generated significantly less react

78 somal doxorubicin plus RF ablation > (186)Re-liposomal doxorubicin > liposomal doxorubicin plus RF ab

79 Stealth liposomal doxorubicin has activity in refractory epithel

80 Liposomal doxorubicin has substantial activity against o

81 his FUS technique to enhance the delivery of liposomal doxorubicin have a pronounced therapeutic effe

82 es were based on the clinical formulation of liposomal doxorubicin (i.e. DOXIL(R)) and were loaded wi

83 raphic findings demonstrated accumulation of liposomal doxorubicin in a peripheral rim of tumor adjac

84 Liposomal doxorubicin in combination with cyclophosphami

85 he clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in

86 MTD) and define the toxic effects of stealth liposomal doxorubicin in combination with gemcitabine in

87 Pegylated liposomal doxorubicin in combination with gemcitabine is

88 developed to examine the activity of Stealth liposomal doxorubicin in platinum- and paclitaxel-refrac

89 e and electron microscopy after injection of liposomal doxorubicin in the hepatic artery, portal vein

90 Combining RF ablation with liposomal doxorubicin increases cell injury and apoptosi

91 ermined amount of the chemotherapeutic drug (liposomal doxorubicin) into the brain.

92 Pegylated liposomal doxorubicin is an effective treatment for HIV-

93 Pegylated-liposomal doxorubicin is more effective and less toxic t

94 oxicity; however, it remains unclear whether liposomal doxorubicin is therapeutically superior to fre

95 Herein, targeted liposomal doxorubicin (L-DXR) was functionalized with re

96 Studies have shown that liposomal doxorubicin (Lipo-DOX), a chemotherapy agent w

97 correlate with response, suggesting that the liposomal doxorubicin may evade this resistance mechanis

98 When RF ablation preceded administration of liposomal doxorubicin, mean intratumoral doxorubicin con

99 ion (n = 43), 1 mg of intravenously injected liposomal doxorubicin (n = 26), or combined therapy (n =

100 n > liposomal doxorubicin plus RF ablation > liposomal doxorubicin) of improved tumor growth control

101 Pegylated-liposomal doxorubicin offers a new alternative for treat

102 umors with C. novyi-NT plus a single dose of liposomal doxorubicin often led to eradication of the tu

103 lator of heat shock proteins) alone and with liposomal doxorubicin on tumor growth and end-point surv

104 133 patients randomized to receive pegylated-liposomal doxorubicin, one achieved a complete clinical

105 three were treated with intravenous (99m)Tc-liposomal doxorubicin only.

106 sus one of the approved drugs (eg, pegylated liposomal doxorubicin or topotecan) in platinum-resistan

107 on and direct intratumoral administration of liposomal doxorubicin, or (e) no treatment.

108 - 1.2 and 31.5 days +/- 3.0 without and with liposomal doxorubicin (P <.01).

109 ablation with intratumoral administration of liposomal doxorubicin (P <.05, compared with RF ablation

110 administration; and liposomal daunorubicin, liposomal doxorubicin, paclitaxel, and interferon-alpha

111 iting toxicities of bortezomib and pegylated liposomal doxorubicin (PegLD).

112 valuated vintafolide combined with pegylated liposomal doxorubicin (PLD) compared with PLD alone.

113 We have investigated pegylated liposomal doxorubicin (PLD) in a clearly defined patient

114 safety of patupilone with those of pegylated liposomal doxorubicin (PLD) in patients with platinum-re

115 ncer agents 4-hydroxytamoxifen and pegylated liposomal doxorubicin (PLD) in the prevention and treatm

116 fficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population.

117 Currently, pegylated liposomal doxorubicin (PLD) is a standard of care for tr

118 acy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezo

119 nter phase III study that compared pegylated liposomal doxorubicin (PLD) to the BV combination.

120 Since pegylated liposomal doxorubicin (PLD) was the most prevalent formu

121 acy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in wo

122 II trial evaluated the bortezomib, pegylated liposomal doxorubicin (PLD), and dexamethasone combinati

123 l therapies had an observable trend ((186)Re-liposomal doxorubicin plus RF ablation > (186)Re-liposom

124 F ablation > (186)Re-liposomal doxorubicin > liposomal doxorubicin plus RF ablation > liposomal doxor

125 decreased in the group treated with (186)Re-liposomal doxorubicin plus RF ablation (0.54 cm(3) +/- 0

126 f) PEGylated liposomes plus RF ablation, (g) liposomal doxorubicin plus RF ablation, (h) (186)Re-PEGy

127 d liposomes plus RF ablation, or (i) (186)Re-liposomal doxorubicin plus RF ablation.

128 Combined RF ablation and liposomal doxorubicin retards tumor growth and may incre

129 In the healthy mouse, non-pegylated liposomal doxorubicin showed a minimal and non-significa

130 trol of tumor growth was better with (186)Re-liposomal doxorubicin than with liposomal doxorubicin al

131 Subsequently, the dose (0.06-2.00 mg) of liposomal doxorubicin, the timing of administration (3 d

132 Combined therapy, as compared with liposomal doxorubicin therapy alone, was also associated

133 technique is able to identify both free and liposomal doxorubicin throughout the spheroid after just

134 show that increased delivery of intravenous liposomal doxorubicin to tumors combined with RF ablatio

135 The starting dose of liposomal doxorubicin was 20 mg/m(2) on day 1 only with

136 Stealth liposomal doxorubicin was administered at 50 mg/m(2) eve

137 Thermosensitive liposomal doxorubicin was administered systemically duri

138 A phase II study of liposomal doxorubicin was conducted in patients with ova

139 Liposomal doxorubicin was selected as a result of its su

140 ar scintigraphy, increased uptake of (99m)Tc-liposomal doxorubicin was visibly apparent in the ablate

141 vestigators selected chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, or topotecan),

142 The responses achieved with liposomal doxorubicin were durable and maintained with m

143 lphavbeta6-specific H2009.1 peptide targeted liposomal doxorubicin, which increased liposomal deliver

144 xicities of a new form of therapy, pegylated-liposomal doxorubicin, with standard combination chemoth

145 The regimen of IL-12 plus liposomal doxorubicin yielded rapid tumor responses and